Stock listing

NASDAQ:KRRO Korro Bio, Inc. Stock

Home listing (NASDAQ) of Korro Bio, Inc.

Follow Korro Bio, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:KRRO

$12.18 USD -0.26 (-2.1%)

Close on Nov 20, 2026

Past year +103.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$12.01 – $12.95 USDNov 20, 2026
Volume
123,520 sharesNov 20, 2026
Market cap
$179.4M USDAt the close on Nov 20, 2026 · price × 14.73M shares outstanding
52-week range
$5.20 – $17.35 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.21M USDMedian day 147,684 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Korro Bio, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:KRRO · Home$12.18 USD-0.26 (-2.1%)123,520$12.03$12.95$12.01$12.44Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:KRRO · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$12.18-0.26-2.1%$12.03$12.95$12.01123,520
$12.44+0.12+1.0%$12.19$13.34$11.85158,098
$12.32-0.39-3.1%$12.69$13.22$12.15158,229
$12.71-0.90-6.6%$13.44$13.61$12.6098,156
$13.61-0.70-4.9%$14.24$14.24$13.1978,960
$14.31-0.10-0.7%$14.23$14.67$13.77203,997
$14.41-1.32-8.4%$15.70$15.70$14.10192,691
$15.73+0.77+5.1%$14.77$16.00$14.77199,161
$14.96+0.21+1.4%$15.14$16.00$14.52175,617
$14.75+0.02+0.1%$14.74$15.74$14.69122,598
$14.73-1.89-11.4%$16.00$16.00$11.50436,189
$16.62+0.76+4.8%$15.93$17.00$15.93263,576
$15.86+0.015+0.1%$15.89$17.35$15.55426,691
$15.85+1.53+10.7%$14.31$15.90$14.00206,732
$14.32+0.115+0.8%$13.99$14.55$13.41130,745
$14.20+0.34+2.5%$13.86$14.28$13.65147,684
$13.86+0.56+4.2%$13.18$14.11$13.04269,308
$13.30+1.28+10.6%$12.73$13.95$12.41322,652
$12.02+0.04+0.3%$11.96$12.30$11.53183,157
$11.98-0.07-0.6%$12.04$12.49$11.28237,437
$12.05+2.76+29.7%$9.40$12.10$9.085476,475
$9.29-0.15-1.6%$9.47$9.77$9.22115,999
$9.44+0.53+5.9%$8.92$9.63$8.92235,039
$8.91+0.42+4.9%$8.58$8.94$8.36134,873
$8.49-0.82-8.8%$9.32$9.38$8.45129,734
$9.31+0.43+4.8%$8.93$9.78$8.53440,177
$8.88+0.07+0.8%$8.62$9.13$8.34216,497
$8.81-0.56-6.0%$9.37$9.39$8.545263,653
$9.37-0.79-7.8%$10.09$10.26$9.32140,406
$10.16-0.42-4.0%$10.60$10.78$10.13133,510
$10.58+0.09+0.9%$10.36$10.64$10.18167,311
$10.49+0.73+7.5%$9.64$10.64$9.50156,998
$9.76-0.21-2.1%$10.20$10.35$9.47142,620
$9.97+0.33+3.4%$9.70$10.10$9.41112,218
$9.64-0.07-0.7%$9.90$9.90$9.478153,134
$9.71-0.20-2.0%$9.93$10.27$9.46588,781
$9.91+0.35+3.7%$9.89$10.01$9.50108,137
$9.56+0.05+0.5%$9.56$9.80$9.3092,876
$9.51-0.06-0.6%$9.49$9.655$9.24132,438
$9.570.000.0%$9.64$9.64$9.40114,420
$9.57-0.26-2.6%$9.71$9.75$9.41197,457
$9.83-0.51-4.9%$10.31$10.31$9.55224,715
$10.34+0.36+3.6%$10.08$10.58$10.01213,478
$9.98-0.04-0.4%$10.12$10.77$9.86290,519
$10.02-1.78-15.1%$11.71$11.95$9.505763,397
$11.80-2.03-14.7%$14.18$14.36$11.76400,440
$13.83-0.24-1.7%$14.15$14.86$13.44304,657
$14.07+0.19+1.4%$13.87$14.20$12.98162,602
$13.88+0.07+0.5%$13.59$15.15$13.56264,804
$13.81+0.75+5.7%$13.28$14.06$13.17197,974
$13.06+0.13+1.0%$12.80$13.16$12.38145,795
$12.93-0.58-4.3%$13.44$13.76$12.87131,501
$13.51+1.27+10.4%$12.03$13.62$11.89119,120
$12.24+0.62+5.3%$11.53$12.30$11.5378,430
$11.62-0.35-2.9%$12.09$12.63$11.3082,728
$11.97-0.27-2.2%$12.26$12.78$11.8281,069
$12.24-0.25-2.0%$12.57$12.64$12.1459,005
$12.49-0.42-3.3%$12.78$13.04$12.2887,957
$12.91-0.35-2.6%$13.13$13.55$12.8067,368
$13.26-0.42-3.1%$13.62$13.69$13.2448,569
$13.68-0.05-0.4%$13.71$13.98$13.2341,275
$13.73+0.66+5.0%$13.14$13.90$13.1479,709
$13.07-0.11-0.8%$13.18$13.60$12.6670,368
$13.18+0.22+1.7%$13.02$13.56$13.0245,706
$12.96-0.99-7.1%$13.77$13.77$12.8364,120

Splits

1 split · NASDAQ:KRRO · every price before a split is adjusted for it

DayRatioWhat
1-for-50Consolidation
Ticker
NASDAQ:KRRO
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Korro Bio, Inc. news

Korro Bio, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
20 in the last 12 months · 109 in all · newest Nov 19, 2026 · oldest 2019
Decks
6 decks · latest August 2026

Where Korro Bio, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:KRRO · Home listing · This pageNASDAQUnited StatesUSD
BOATS:KRROBOATSUnited StatesUSD

Valuation

EV/sales 57.6× against a median of 15.6×: 6th lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$74.36M USD
P/E
Loss
EV/sales
57.6×
EV/EBITDA
Negative EBITDA
Price/book
2.0×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.46

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Korro Bio, Inc. · NASDAQ:KRROUS$179.4MUS$74.36Mn/a57.6×n/a2.0×n/a0.0×1.46
Inventage Lab, Inc. · KRX:389470US$185.9MUS$113.3Mn/a61.3×n/a2.8×−127.0%0.2×n/a
Inhibikase Therapeutics, Inc. · NASDAQ:IKTUS$185.2M−US$8.17Mn/an/an/a1.0×n/a0.0×1.50
Antengene Corporation Limited · HKEX:6996US$183.1MUS$107.1Mn/a6.8×n/a1.3×−227.0%0.3×n/a
Whitehawk Therapeutics, Inc. · NASDAQ:WHWKUS$181.2MUS$11.70Mn/an/an/a1.1×n/a0.0×1.35
Sol-Gel Technologies Ltd. · NASDAQ:SLGLUS$180.6MUS$137.0Mn/a95.4×n/a4.2×n/a0.0×0.67
Tanvex BioPharma, Inc. · TWSE:6541US$180.5MUS$225.7Mn/a11.3×n/a1.2×−222.8%0.4×n/a
Vogenx Inc · NASDAQ:VOGXUS$176.3MUS$94.21Mn/an/an/a2.1×n/a0.0×n/a
MediWound Ltd. · NASDAQ:MDWDUS$175.5MUS$155.9Mn/a15.6×n/a5.5×−235.0%0.3×0.64
Nanexa AB · OMXSTO:NANEXAUS$175.1MUS$170.1Mn/a51.4×n/a13.5×−72.5%0.0×n/a
Compugen Ltd. · NASDAQ:CGENUS$174.3MUS$59.55M4.8×0.8×n/a2.1×47.9%0.0×1.49
Median of the othersUS$180.6MUS$110.2M4.8×15.6×2.1×−174.9%0.0×1.35

Forecasts

8 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
21.50 USD · Analysts' mean
EPS, year to Dec 2026
-4.75 · 10 analysts
Revenue, year to Dec 2026
1.74M · 9 analysts

Team and board

Officers

OfficerRole
Ram AiyarChief Executive Officer & President
Todd ChappellChief Operating Officer
Jeffrey M. CerioSVP, General Counsel
Gaozhong ZhuSVP, CMC & Technical Operations
Jean-François FormelaCo-Founder & Director
Loïc VincentChief Scientific Officer
Nessan BerminghamCo-Founder & Chairman
Stephanie EngelsChief People Officer

Board

DirectorRole
Nessan BerminghamCo-Founder & Chairman
Ali BehbahaniDirector
Jean-François FormelaCo-Founder & Director
Katharine KnobilDirector
Rachel MeyersDirector
Ram AiyarChief Executive Officer & President
Timothy R. PearsonDirector

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−11.4%
Q2 2026Aug 6, 2026 · Before open+5.4%
Q1 2026May 7, 2026−9.7%
Q4 2025Mar 12, 2026 · After close+11.3%
Q3 2025Nov 12, 2025 · After close−79.3%
Q2 2025Aug 12, 2025 · Before open+6.3%
Q1 2025May 7, 2025 · After close+10.6%
Q4 2024Mar 24, 2025 · Before open+1.1%
Q3 2024Nov 12, 2024 · After close−15.6%
Q2 2024Aug 13, 2024 · After close+9.2%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · After close+5.4%
Q4 2023Mar 26, 2024 · After close+1.8%
Q3 2023Nov 2, 2023 · After close+6.0%
Q2 2023Aug 10, 2023−4.1%
Q1 2023May 12, 2023−5.6%
Q4 2022Mar 10, 2023+3.1%
Q3 2022Nov 8, 2022−5.8%
Q2 2022Aug 9, 2022−3.1%
Q1 2022May 4, 2022+1.6%
Q4 2021Mar 15, 2022+29.4%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck26 slidesAugust 2026
Investor Presentation (May 2026)Investor deck5 slidesMay 19, 2026
Investor Day (January 2026)Investor day54 slidesJan 27, 2026
Investor Day (January 2026)Investor day32 slidesJan 27, 2026
J.P. Morgan Healthcare Conference 2024Conference36 slidesJan 9, 2024
Merger or Acquisition (July 2023)Merger or acquisition30 slidesJuly 2023

Open Decks

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Revenue6.39M2.27M0014.1M37.0M28.9M
Cost of revenue4.28M3.56M3.63M2.51M3.84M1.58M16.8M654.0K531.0K
Gross profit2.11M2.27M-3.63M-2.51M10.2M35.4M12.1M-654.0K-531.0K
Research and development65.6M63.6M57.3M42.2M60.9M37.4M18.8M11.9M12.0M
Selling, general and administrative28.2M30.5M24.0M16.8M11.7M
Operating income-121.9M-91.9M-84.5M-59.0M-84.0M-27.6M-20.7M-18.9M-16.3M
Depreciation and amortization4.28M3.56M3.63M2.51M2.77M1.15M813.0K654.0K531.0K
EBITDA-117.6M-88.3M-80.9M-56.5M-81.3M-26.4M-19.9M-18.3M-15.8M
Interest expense961.0K764.0K0106.0K174.0K
Income before tax-116.6M-83.4M-81.1M-58.0M-84.7M-26.5M-18.7M-19.2M-20.2M
Income tax637.0K141.0K27.0K10.0K15.0K35.0K01
Net income-117.3M-83.6M-81.2M-58.0M-84.7M-26.5M-18.7M-19.2M-20.2M
Earnings per share, basic-12.48-9.37-53.08-227.42-2.47-0.82-2.29-12.53-28.79
Earnings per share, diluted-12.48-9.37-53.08-227.42-2.47-0.82-2.29-12.53-28.79

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash and equivalents21.8M55.6M166.2M36.3M79.6M220.3M200.2M42.2M17.9M
Short-term investments53.3M70.5M018.9M51.1M17.2M
Receivables969.0K1.70M0449.0K144.0K340.0K805.0K161.0K
Inventory-144.0K
Current assets82.4M131.5M172.7M57.1M134.7M225.1M221.4M42.9M18.0M
Property, plant and equipment8.16M27.7M15.7M9.87M5.52M7.29M1.76M1.51M
Total assets113.5M226.2M221.7M73.7M185.4M264.7M223.2M44.5M19.8M
Accounts payable1.65M3.99M7.28M2.60M2.75M5.51M1.22M1.86M994.0K
Current liabilities11.9M15.0M19.5M8.70M11.4M26.6M52.8M3.77M2.23M
Long-term debt180.0K349.0K
Total debt43.5M44.8M33.2M10.0M833.0K46.0M180.0K349.0K46.7M
Total liabilities62.1M65.8M51.8M8.91M54.5M72.2M55.9M4.12M49.4M
Shareholders' equity51.4M160.4M169.9M-99.0M-42.2M192.5M167.4M-48.3M-29.6M
Shares outstanding9.42M9.38M8.02M268.5K34.6M34.0M30.8M2.08M30.9M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations-78.6M-60.1M-67.3M-53.6M-76.1M-45.2M34.2M-17.0M-14.6M
Capital spending-518.0K-17.9M-7.84M-5.14M-2.91M-6.67M-1.06M-436.0K-1.86M
Free cash flow-79.1M-78.0M-75.1M-58.8M-79.0M-51.9M33.2M-17.5M-16.5M
Cash from investing44.0M-123.3M11.2M11.1M-66.1M10.4M-18.3M-436.0K-1.86M
Cash from financing685.0K69.4M187.8M18.0K1.36M56.7M142.0M41.7M28.0M
Change in cash-33.8M-114.1M131.6M-42.6M-140.8M21.9M158.0M24.3M11.5M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
144 · Notice of proposed saleNov 12, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeNov 12, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 27, 2026Big-stake noticeSEC
4 · Change in ownershipOct 26, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportOct 22, 2026Current reportSEC
8-K · Current reportOct 5, 2026Current reportSEC
4 · Change in ownershipSep 15, 2026Insider tradeSEC
144 · Notice of proposed saleSep 14, 2026Other filingsSEC
144 · Notice of proposed saleSep 14, 2026Other filingsSEC
4 · Change in ownershipSep 14, 2026Insider tradeSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
144 · Notice of proposed saleSep 11, 2026Other filingsSEC
4 · Change in ownershipSep 10, 2026Insider tradeSEC
144 · Notice of proposed saleSep 9, 2026Other filingsSEC
144 · Notice of proposed saleSep 8, 2026Other filingsSEC
4 · Change in ownershipAug 28, 2026Insider tradeSEC
144 · Notice of proposed saleAug 26, 2026Other filingsSEC
144 · Notice of proposed saleAug 26, 2026Other filingsSEC
4 · Change in ownershipAug 21, 2026Insider tradeSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
144 · Notice of proposed saleAug 19, 2026Other filingsSEC
8-K · Current reportAug 19, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
4 · Change in ownershipAug 13, 2026Insider tradeSEC
144 · Notice of proposed saleAug 11, 2026Other filingsSEC
144 · Notice of proposed saleAug 11, 2026Other filingsSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-K · Current reportAug 6, 2026ResultsSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 4, 2026Big-stake noticeSEC
144 · Notice of proposed saleAug 4, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2026Big-stake noticeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 17, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
144 · Notice of proposed saleJul 6, 2026Other filingsSEC
144 · Notice of proposed saleJul 2, 2026Other filingsSEC
144 · Notice of proposed saleJul 2, 2026Other filingsSEC
4 · Change in ownershipJun 24, 2026Insider tradeSEC
144 · Notice of proposed saleJun 24, 2026Other filingsSEC
144 · Notice of proposed saleJun 24, 2026Other filingsSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
144 · Notice of proposed saleJun 23, 2026Other filingsSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
144 · Notice of proposed saleJun 22, 2026Other filingsSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
4 · Change in ownershipJun 17, 2026Insider tradeSEC
144 · Notice of proposed saleJun 16, 2026Other filingsSEC
144 · Notice of proposed saleJun 16, 2026Other filingsSEC
144 · Notice of proposed saleJun 16, 2026Other filingsSEC
144 · Notice of proposed saleJun 16, 2026Other filingsSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
8-K · Current reportJun 11, 2026Meeting outcomeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipJun 1, 2026Insider tradeSEC
144 · Notice of proposed saleMay 29, 2026Other filingsSEC
4 · Change in ownershipMay 28, 2026Insider tradeSEC
8-K · Current reportMay 19, 2026Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
424B3 · ProspectusMay 12, 2026Offer documentSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
ARS · Annual report to shareholdersApr 16, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 16, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 16, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 2, 2026Big-stake noticeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 2, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 27, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveMar 23, 2026Other filingsSEC
424B5 · ProspectusMar 20, 2026Offer documentSEC
CORRESP · Letter to the SECMar 18, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 18, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeMar 17, 2026Big-stake noticeSEC
S-3 · Registration statementMar 13, 2026Offer documentSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
4 · Change in ownershipMar 12, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 12, 2026Big-stake noticeSEC
10-K · Annual reportMar 12, 2026Annual reportSEC
8-K · Current reportMar 12, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeMar 11, 2026Big-stake noticeSEC
8-K · Current reportMar 9, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 13, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 5, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 30, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansJan 27, 2026Offer documentSEC
8-K · Current reportJan 27, 2026Current reportSEC
8-K · Current reportJan 15, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJan 5, 2026Big-stake noticeSEC
8-K · Current reportDec 18, 2025Management or board changeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
4 · Change in ownershipDec 16, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
8-K · Current reportOct 8, 2025Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
8-K/A · Current report, amendedJun 18, 2025Meeting outcomeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
4 · Change in ownershipJun 12, 2025Insider tradeSEC
8-K · Current reportJun 11, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 7, 2025Quarterly reportSEC
8-K · Current reportMay 7, 2025ResultsSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
4 · Change in ownershipApr 1, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 1, 2025Insider tradeSEC
8-K · Current reportMar 27, 2025Management or board changeSEC
S-8 · Registration statement for employee plansMar 18, 2025Offer documentSEC
10-K · Annual reportMar 18, 2025Annual reportSEC
8-K · Current reportMar 18, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
3 · Initial statement of ownershipFeb 11, 2025Insider tradeSEC
8-K · Current reportFeb 11, 2025Management or board changeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 5, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
4 · Change in ownershipFeb 5, 2025Insider tradeSEC
8-K · Current reportJan 13, 2025Current reportSEC
424B3 · ProspectusDec 10, 2024Offer documentSEC
424B3 · ProspectusDec 10, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveDec 10, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveDec 10, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveDec 9, 2024Other filingsSEC
424B5 · ProspectusDec 6, 2024Offer documentSEC
CORRESP · Letter to the SECDec 6, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 6, 2024Other filingsSEC
POS AM · Amendment to an effective registrationDec 2, 2024Offer documentSEC
POS AM · Amendment to an effective registrationDec 2, 2024Offer documentSEC
S-3 · Registration statementDec 2, 2024Offer documentSEC
424B3 · ProspectusNov 21, 2024Offer documentSEC
424B3 · ProspectusNov 21, 2024Offer documentSEC
8-K · Current reportNov 21, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
4 · Change in ownershipNov 12, 2024Insider tradeSEC
424B3 · ProspectusNov 12, 2024Offer documentSEC
424B3 · ProspectusNov 12, 2024Offer documentSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
144 · Notice of proposed saleNov 12, 2024Other filingsSEC
424B3 · ProspectusNov 4, 2024Offer documentSEC
424B3 · ProspectusNov 4, 2024Offer documentSEC
8-K · Current reportNov 4, 2024Current reportSEC
4 · Change in ownershipOct 18, 2024Insider tradeSEC
144 · Notice of proposed saleOct 17, 2024Other filingsSEC
144 · Notice of proposed saleOct 16, 2024Other filingsSEC
424B3 · ProspectusSep 16, 2024Offer documentSEC
424B3 · ProspectusSep 16, 2024Offer documentSEC

This page holds 200 of 836 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Korro Bio, Inc.’s releases · as of Nov 11, 2026

Common shares
14,725,646
Fully diluted
14,726,646

Fully diluted

LineSharesAs of
Common shares14,725,646
Options and RSUs1,000Nov 11, 2026

Warrants and options

Lot
Stock options · US$14.41 · expire about Nov 2036

Share count over time

CountShares
Nov 22, 202614,725,646

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Lynx1 Capital Management LP1.54MUS$15.3MSep 30, 2026
NEA Management Company, LLC1.3MUS$12.9MSep 30, 2026
Adage Capital Partners Gp, L.L.C.1MUS$9.91MSep 30, 2026
Balyasny Asset Management L.P.869KUS$8.62MSep 30, 2026
BlackRock845KUS$8.37MSep 30, 2026
Vanguard784KUS$7.76MSep 30, 2026
Atlas Venture Life Science Advisors, LLC773KUS$7.66MSep 30, 2026
Nantahala Capital Management, LLC680KUS$6.74MSep 30, 2026
ADAR1 Capital Management, LLC540KUS$5.35MSep 30, 2026
Affinity Asset Advisors, LLC532KUS$5.27MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Kalehua Capital Management LLC474KUS$4.69MSep 30, 2026
Driehaus Capital Management LLC450KUS$4.46MSep 30, 2026
Venrock Adviser, LLC443KUS$4.39MSep 30, 2026
TCG Crossover Management, LLC416KUS$4.13MSep 30, 2026
Siren, L.L.C.348KUS$3.45MSep 30, 2026
JPMorgan302KUS$2.88MSep 30, 2026
Geode Capital288KUS$2.85MSep 30, 2026
72 Investment Holdings, LLC277KUS$2.74MSep 30, 2026
State Street244KUS$2.42MSep 30, 2026
Two Sigma161KUS$1.6MSep 30, 2026
UBS154KUS$1.53MSep 30, 2026
AQR Capital Management LLC126KUS$1.25MSep 30, 2026
Goldman Sachs107KUS$1.06MSep 30, 2026
Quantinno Capital Management LP91,733US$909KSep 30, 2026
D. E. Shaw & Co., Inc.90,107US$893KSep 30, 2026
Northern Trust87,188US$864KSep 30, 2026
Opaleye Management Inc.69,348US$687KSep 30, 2026
Renaissance Technologies65,662US$651KSep 30, 2026
Emerald Mutual Fund Advisers Trust65,442US$649KSep 30, 2026
F/m Investments LLC65,442US$649KSep 30, 2026
Millennium60,000US$595KSep 30, 2026
HSBC56,350US$557KSep 30, 2026
Raymond James Financial Inc53,109US$526KSep 30, 2026
Morgan Stanley48,991US$486KSep 30, 2026
Fidelity39,643US$393KSep 30, 2026
BNP Paribas38,717US$384KSep 30, 2026
Acadian Asset Management LLC37,422US$368KSep 30, 2026
BNY33,632US$333KSep 30, 2026
AIHC Capital Management Ltd30,265US$300KSep 30, 2026
XTX Topco Ltd29,288US$290KSep 30, 2026
Prosperity Wealth Management, Inc.29,000US$287KSep 30, 2026
Schwab27,197US$270KSep 30, 2026
Nuveen22,132US$219KSep 30, 2026
Quadrature Capital Ltd21,525US$213KSep 30, 2026
Los Angeles Capital Management LLC20,967US$208KSep 30, 2026
North Star Investment Management Corp.20,600US$204KSep 30, 2026
Guggenheim Capital LLC18,040US$179KSep 30, 2026
T. Rowe Price17,634US$175KSep 30, 2026
Citigroup Inc16,268US$161KSep 30, 2026
American Century15,790US$156KSep 30, 2026

This page holds 50 of 101 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund311KUS$4.1MJun 30, 2026
iShares Russell 2000 ETF263KUS$3.47MJun 30, 2026
Vanguard Extended Market Index Fund135KUS$1.78MJun 30, 2026
Fidelity Small Cap Index Fund122KUS$1.26MJul 31, 2026
Vanguard Strategic Small-Cap Equity Fund106KUS$1.4MJun 30, 2026
iShares Russell 2000 Value ETF78,719US$1.04MJun 30, 2026
F/m Emerald Life Sciences Innovation ETF62,855US$843KMay 31, 2026
iShares Russell 2000 Growth ETF56,704US$747KJun 30, 2026
Fidelity Extended Market Index Fund35,064US$470KMay 31, 2026
Vanguard Russell 2000 Index Fund34,066US$457KMay 31, 2026
Show 50 holders
HolderSharesValueAs of
iShares Micro-Cap ETF34,046US$449KJun 30, 2026
Schwab Small-Cap Index Fund26,870US$279KJul 31, 2026
Vanguard Health Care Index Fund21,772US$292KMay 31, 2026
Master Small Cap Index Series18,948US$250KJun 30, 2026
Nuveen Small Cap Blend Index Fund14,880US$154KJul 31, 2026
Small Company Growth Portfolio14,620US$193KJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF14,179US$187KJun 30, 2026
Fidelity Small Cap Value Index Fund12,814US$169KJun 30, 2026
EQ/2000 Managed Volatility Portfolio11,376US$150KJun 30, 2026
Fidelity Total Market Index Fund11,313US$152KMay 31, 2026
Fidelity Nasdaq Composite Index Fund10,496US$141KMay 31, 2026
Dimensional U.S. Small Cap ETF9,978US$103KJul 31, 2026
Fidelity Series Total Market Index Fund9,938US$133KMay 31, 2026
T. Rowe Price Extended Equity Market Index Fund8,500US$112KJun 30, 2026
Fidelity ZERO Total Market Index Fund7,460US$77,360Jul 31, 2026
EQ/Small Company Index Portfolio7,000US$92,260Jun 30, 2026
Small Cap Index Fund5,888US$77,604Jun 30, 2026
Diversified Equity Alpha Master Portfolio5,321US$70,131Jun 30, 2026
Global X Russell 2000 ETF5,318US$55,148Jul 31, 2026
EQ/AB Small Cap Growth Portfolio5,180US$68,272Jun 30, 2026
Vanguard Russell 2000 Value Index Fund5,064US$67,908May 31, 2026
Goldman Sachs Absolute Return Tracker Fund4,883US$64,358Jun 30, 2026
Vanguard Balanced Index Fund4,762US$62,763Jun 30, 2026
Avantis U.S. Small Cap Equity ETF4,640US$62,222May 31, 2026
LVIP State Street Small-Cap Index Fund4,500US$59,310Jun 30, 2026
Fidelity ZERO Extended Market Index Fund4,390US$45,524Jul 31, 2026
Small-Cap Index Portfolio3,414US$44,997Jun 30, 2026
State Street Small/Mid Cap Equity Index Portfolio3,400US$44,812Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund3,358US$44,258Jun 30, 2026
iShares Russell 3000 ETF3,244US$42,756Jun 30, 2026
Bridge Builder Small/Mid Cap Value Fund2,830US$37,299Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio2,411US$31,777Jun 30, 2026
Small Cap Index Fund2,289US$30,695May 31, 2026
1290 VT Micro Cap Portfolio2,272US$29,945Jun 30, 2026
NVIT Small Cap Index Fund2,271US$29,932Jun 30, 2026
Fidelity Flex Small Cap Index Fund1,951US$20,232Jul 31, 2026
Fidelity Small Cap Growth Index Fund1,913US$25,213Jun 30, 2026
DWS Small Cap Index VIP1,744US$22,986Jun 30, 2026
T. Rowe Price Small-Cap Index Fund1,679US$22,129Jun 30, 2026
iShares Russell Small/Mid-Cap Index Fund1,629US$16,893Jul 31, 2026

This page holds 50 of 91 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Formela Jean Francois
Director
Sale33,175USD 14.30US$474KNov 12, 2026
Formela Jean Francois
Director
Sale6,870USD 14.30US$98,241Nov 12, 2026
Formela Jean Francois
Director
Sale19,042USD 15.00US$286KNov 11, 2026
Formela Jean Francois
Director
Sale2,984USD 15.60US$46,550Nov 11, 2026
Formela Jean Francois
Director
Sale3,944USD 15.00US$59,160Nov 11, 2026
Formela Jean Francois
Director
Sale617USD 15.60US$9,625Nov 11, 2026
Lynx1 Capital Management LP
10% owner
Buy25,124USD 11.75US$295KOct 26, 2026
Lynx1 Capital Management LP
10% owner
Buy2,510USD 12.11US$30,386Oct 23, 2026
Lynx1 Capital Management LP
10% owner
Buy12,175USD 9.68US$118KOct 22, 2026
Lynx1 Capital Management LP
10% owner
Buy40,000USD 11.04US$441KOct 22, 2026
All 46 trades
TradeTradeSharesPriceValueDate
Formela Jean Francois
Director
Sale31,888USD 14.12US$450KSep 14, 2026
Formela Jean Francois
Director
Sale6,602USD 14.12US$93,220Sep 14, 2026
Formela Jean Francois
Director
Sale8,450USD 13.99US$118KSep 11, 2026
Formela Jean Francois
Director
Sale1,750USD 13.99US$24,483Sep 11, 2026
Dolan Oliver
Officer: Senior Vice President, Finance
Sale5USD 13.72US$69Sep 11, 2026
Dolan Oliver
Officer: Senior Vice President, Finance
Sale6USD 13.60US$82Sep 9, 2026
Dolan Oliver
Officer: Senior Vice President, Finance
Sale7,347USD 13.51US$99,258Sep 8, 2026
Formela Jean Francois
Director
Sale249USD 13.96US$3,476Aug 26, 2026
Formela Jean Francois
Director
Sale51USD 13.96US$712Aug 26, 2026
Formela Jean Francois
Director
Sale23,584USD 14.00US$330KAug 19, 2026
Formela Jean Francois
Director
Sale4,884USD 14.00US$68,376Aug 19, 2026
Formela Jean Francois
Director
Sale1,775USD 13.96US$24,779Aug 11, 2026
Formela Jean Francois
Director
Sale368USD 13.96US$5,137Aug 11, 2026
Lynx1 Capital Management LP
10% owner
Buy1,462USD 13.19US$19,284Aug 10, 2026
Lynx1 Capital Management LP
10% owner
Buy5,222USD 11.40US$59,531Aug 6, 2026
Aiyar Ram
Director, Officer: President and CEO
Sale5,802USD 10.84US$62,894Aug 4, 2026
Formela Jean Francois
Director
Sale817USD 13.96US$11,405Jul 6, 2026
Formela Jean Francois
Director
Sale8,506USD 13.96US$119KJul 6, 2026
Formela Jean Francois
Director
Sale85,955USD 14.03US$1.21MJul 2, 2026
Formela Jean Francois
Director
Sale14,745USD 14.03US$207KJul 2, 2026
Formela Jean Francois
Director
Sale40,679USD 14.60US$594KJun 24, 2026
Formela Jean Francois
Director
Sale666USD 14.98US$9,977Jun 24, 2026
Formela Jean Francois
Director
Sale6,979USD 14.60US$102KJun 24, 2026
Formela Jean Francois
Director
Sale114USD 14.98US$1,708Jun 24, 2026
Formela Jean Francois
Director
Sale101,579USD 14.25US$1.45MJun 23, 2026
Formela Jean Francois
Director
Sale17,426USD 14.25US$248KJun 23, 2026
Formela Jean Francois
Director
Sale3,382USD 13.95US$47,179Jun 22, 2026
Formela Jean Francois
Director
Sale580USD 13.95US$8,091Jun 22, 2026
Dolan Oliver
Officer: Senior Vice President, Finance
Sale3,383USD 10.83US$36,638Jun 16, 2026
Cerio Jeffrey
Officer: General Counsel
Sale6,609USD 10.83US$71,575Jun 16, 2026
Vincent Loic A
Officer: Chief Scientific Officer
Sale3,418USD 10.83US$37,017Jun 16, 2026
Chappell Todd
Officer: Chief Operating Officer
Sale3,168USD 10.83US$34,309Jun 16, 2026
Aiyar Ram
Director, Officer: President and CEO
Sale15,152USD 12.98US$197KMay 29, 2026
Formela Jean Francois
Director
Sale2,441USD 13.95US$34,052May 28, 2026
Formela Jean Francois
Director
Sale419USD 13.95US$5,845May 28, 2026
Nichols Weston
10% owner
Buy520USD 10.60US$5,512Mar 31, 2026

Big stakes

StakeStakeSharesDateFiling
Lynx1 Capital Management LP10.70%1.54MMar 31, 2026Schedule 13G
Venrock Healthcare Capital Partners III, L.P.9.90%1.47MSep 30, 2026Schedule 13G
New Enterprise Associates 17, L.P.9.90%1.44MMar 10, 2026Schedule 13D
Adage Capital Management, L.P.6.79%1MSep 30, 2026Schedule 13G
Nantahala Capital Management, LLC6.37%600KDec 31, 2025Schedule 13G
Balyasny Asset Management L.P.5.90%869KSep 30, 2026Schedule 13G
Atlas Venture Fund XI, L.P.4.90%707KJun 24, 2026Schedule 13D

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Ali Behbahani
Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); NeueHealth Inc (Director · Since at least Oct 2, 2025); Arcellx Inc (Director · Since at least Feb 3, 2022); Monte Rosa Therapeutics, Inc. (Director · Since at least Jun 23, 2021); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Black Diamond Therapeutics, Inc. (Director · Since at least Jan 29, 2020); Adaptimmune Therapeutics PLC (Director · Since at least Jul 2, 2019); CRISPR Therapeutics AG (Director · Since at least Jun 11, 2019); Minerva Surgical, Inc. (Director · Oct 21, 2021 – Jun 10, 2022 · Past); CVRx, Inc. (Director · Jun 29, 2021 – Jun 4, 2024 · Past); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 3, 2023 · Past)
Director · Since at least Nov 3, 2023
Jean-François Formela
Other companies: ImageneBio, Inc. (Director · Mar 25, 2021 – Jun 7, 2024 · Past); Translate Bio Inc (Director · Jun 27, 2018 – Sep 14, 2021 · Past); Spero Therapeutics, Inc. (Director · Nov 1, 2017 – Aug 17, 2021 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – Jun 14, 2022 · Past); Egalet Corporation (Director · Feb 5, 2014 – Feb 11, 2014 · Past); Oruka Therapeutics, Inc. (Director · Feb 10, 2012 – Oct 22, 2012 · Past); Horizon Pharma PLC (Director · Jul 28, 2011 – Mar 2, 2012 · Past)
Co-Founder & Director · Since at least Nov 3, 2023
Robert Langer
Other companies: Seer, Inc. (Director · Since at least Dec 3, 2020); Lyra Therapeutics, Inc. (David H. Koch Institute Professor, Massachusetts Institute of Technology · Since at least Apr 30, 2020); Moderna, Inc. (Director · Dec 7, 2018 – May 6, 2024 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – Oct 14, 2019 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 12, 2018 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Jun 21, 2016 · Past); Ocata Therapeutics Inc (Director · Oct 4, 2011 – Feb 10, 2016 · Past)
Director · Oct 2, 2019 – Aug 17, 2022 · Past
Peter P Pfreundschuh
Other companies: Y mAbs Therapeutics (EVP, CFO and Treasurer · Since at least Jun 28, 2024); Voyager Therapeutics, Inc. (Chief Financial Officer · Sep 19, 2022 – Feb 21, 2024 · Past); UroGen Pharma Ltd. (Chief Financial Officer · Jan 1, 2019 – Oct 15, 2020 · Past); Sucampo Pharmaceuticals Inc (CFO · Mar 20, 2017 – Feb 13, 2018 · Past); Immunomedics Inc (Chief Financial Officer · Aug 20, 2015 – Aug 20, 2015 · Past)
Chief Financial Officer · Dec 1, 2020 – Feb 18, 2022 · Past
Marc Cohen
Other companies: C4 Therapeutics, Inc. (In MemoriamCo-Founder & Executive Chairman Emeritus · Since at least Oct 1, 2020)
Director · Oct 2, 2019 – Jun 21, 2022 · Past
Michael Bookman
Other companies: Immuneering Corporation (Chief Legal Officer, Secretary · Since at least Jul 29, 2021)
General Counsel and Secretary · Jan 19, 2021 – Apr 20, 2021 · Past
Dana Charles HiltChief Medical Officer · Oct 2, 2019 – Apr 20, 2021 · Past
David L LucchinoDirector · Oct 2, 2019 – Jun 11, 2024 · Past
Gaozhong ZhuSVP, CMC & Technical Operations · Since at least Apr 1, 2025
Jeffrey M. CerioSVP, General Counsel · Since at least Nov 12, 2024
All 21 people
PersonSeat
Katharine KnobilDirector · Since at least Nov 12, 2024
Loïc VincentChief Scientific Officer · Since at least Mar 31, 2025
Nessan BerminghamCo-Founder & Chairman · Since at least Nov 4, 2026
Oliver DolanSenior Vice President, Finance · Since at least Feb 11, 2025
Quentin McCubbinChief Manufacturing Officer · Jan 19, 2021 – Jan 26, 2023 · Past
Rachel MeyersDirector · Since at least Nov 4, 2026
Ram AiyarPresident and CEO, Director · Since at least Nov 3, 2023
Stephanie EngelsChief People Officer · Since at least Nov 4, 2026
Timothy R. PearsonDirector · Since at least Nov 4, 2026
Todd ChappellChief Operating Officer · Since at least Nov 3, 2023
Vineet AgarwalChief Financial Officer · Nov 3, 2023 – Feb 3, 2025 · Past

Open People

Log in to ask 6ix AI your own questions about Korro Bio, Inc.